Vaccine News and Research

Latest Vaccine News and Research

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

FDA Commissioner Margaret A. Hamburg today sent a letter to America's health care professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on safety monitoring of the 2009 H1N1 vaccines.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

18 Jan 2010

Study raises concerns about drug-resistant HIV

The emergence of drug-resistant strains of HIV could one day threaten efforts to control the global HIV pandemic, according to a study published online Thursday in the journal Science, HealthDay News/U.S. News & World Report reports. The researchers based their findings on "a mathematical model that tracks the transmission of multiple strains of HIV" in San Francisco, the news service writes (1/14).

18 Jan 2010

WHO official rejects claims agency overhyped threat of H1N1

Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports.

18 Jan 2010

Early immune response needed for 'hit-and-hide' cancer viruses

Retroviruses such as HIV and HTLV-1 don't hit-and-run, they hit-and-hide. They slip into host cells and insert their own DNA into the cell's DNA, and from this refuge they establish an infection that lasts a lifetime.

14 Jan 2010

Scripps Research scientists produce chemically complex compound

In 1993 researchers discovered a chemical compound in a sponge off Palau, an island nation in the Pacific Ocean, that has shown anticancer, antibacterial, and antifungal pharmaceutical promise. But that wasn't its greatest allure, at least not for chemists.

13 Jan 2010

Whitley urges public to get vaccinated against H1N1 influenza virus

With several months left in the influenza season and growing supplies of vaccine, now is an opportune time to get vaccinated against the 2009 H1N1 influenza virus, says Richard Whitley, M.D., director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases and current president of the Infectious Diseases Society of America (IDSA).

13 Jan 2010

Work provides new insight into potential therapeutic treatments for cancer diseases

An enzyme that normally helps break down stored fats goes into overdrive in some cancer cells, making them more malignant, according to new findings by a team at The Scripps Research Institute.

13 Jan 2010

Teenage girls are not receiving HPV vaccine, says report

In 2006, the Food and Drug Administration (FDA) approved the Human Papilloma Virus (HPV) vaccine for girls and women ages 9 to 26. As part of Cervical Cancer Awareness Month in January, experts at The University of Texas M. D. Anderson Cancer Center review what we have learned about this controversial vaccine in the past four years.

13 Jan 2010

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

ERA-NET PathoGenoMics, an initiative of the European Commission aimed at advancing transnational genome-based research programs on human-pathogenic microorganisms, announced today the third international joint call. The third joint call allocated €8.5 Million over 3 years to relevant research projects which will be provided by ERA-NET PathoGenoMics partner organizations from Austria, France, Germany, Hungary, Israel, Portugal, Slovenia and Spain.

13 Jan 2010

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

A record-breaking 8,300 front-line health care professionals participated in an accredited, online education program about H1N1 vaccination in November 2009 alone.

13 Jan 2010

Microbix Biosystems signs partnership agreement with Therapure Biopharma

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

13 Jan 2010

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

After working to ensure the U.S. had access to enough H1N1 (swine flu) vaccine, health officials may now face a new dilemma - a vaccine surplus, the Associated Press reports.

12 Jan 2010

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate Corporation today announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.

12 Jan 2010

Phase I clinical trial of XRX-001 for yellow fever initiated

Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

With today's release of a landmark study by the Institute of Medicine (IOM), Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, finding that inadequate public-health resources are being allocated to national and local prevention, control, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) today renewed its call for the Administration, Congress, and the entire health care system to take immediate and decisive action to implement the report's key recommendations.

12 Jan 2010

Vaccine News and Research

Latest Vaccine News and Research

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

New findings may yield novel therapies for chronic neurodegenerative diseases

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

Study raises concerns about drug-resistant HIV

WHO official rejects claims agency overhyped threat of H1N1

Early immune response needed for 'hit-and-hide' cancer viruses

Scripps Research scientists produce chemically complex compound

Whitley urges public to get vaccinated against H1N1 influenza virus

Work provides new insight into potential therapeutic treatments for cancer diseases

Teenage girls are not receiving HPV vaccine, says report

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

Record-breaking 8,300 health care professionals participate in online H1N1 vaccination education program

Microbix Biosystems signs partnership agreement with Therapure Biopharma

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Media outlets examine U.S. plans for leftover H1N1 vaccine, efforts to keep flu vaccine production on track

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

Phase I clinical trial of XRX-001 for yellow fever initiated

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in